Is this panel suitable for hereditary risk?

No, somatic panels assess the current tumor; for inherited risk use a hereditary cancer panel.

Does ctDNA replace tissue biopsy?

ctDNA usually complements tissue biopsy and is especially useful when tissue access is limited.

Yes, comprehensive panels typically include these biomarkers.

Genetic Tests

NGS cancer panels analyze dozens of key genes simultaneously, supporting targeted therapy selection and disease monitoring.

Targeted sequencing of cancer-related genes to identify actionable mutations and biomarkers.

For cancer patients to inform targeted therapy choice, prognosis and treatment monitoring.

Fresh tumor tissue, FFPE block or blood sample for circulating tumor DNA (ctDNA).

Custom panels covering EGFR, KRAS, BRAF, ALK, ROS1, HER2 and other key cancer genes.

Report of somatic mutations, TMB, MSI status and evidence-based therapeutic implications.

FFPE quality may affect sensitivity. Rare variants may require confirmation by complementary assays.

To Be Added

To Be Added

Multiple solid tumors and hematologic malignancies.

Contact Gene Negar Ayandegan for sample submission, laboratory collaboration, or more information.